Enoda utilizes novel molecular tools and high-throughput screening to map underexplored cellular pathways for therapeutic enhancement. This approach allows them to rapidly engineer optimal cell phenotypes for specific disease indications. The company focuses on precisely engineering cell therapies to maximize their disease-fighting potential.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cell therapy development often focuses on well-known receptors and cell types, potentially overlooking other biological pathways that could enhance therapeutic efficacy. This narrow focus can limit the potential of cell therapies to address a broader range of diseases.
Solution
Enoda employs high-throughput screening and systems immunology to engineer cell therapies by mapping underexplored biological pathways. The company aims to create optimized cell phenotypes for a wider range of diseases by using molecular tools to rapidly and unbiasedly map how these pathways improve the therapeutic function of cells. Enoda combines its molecular tooling platform with high-throughput screening and systems immunology to engineer the right cell type with the right tools for the right indication. The company's goal is to precisely engineer every facet of the cell to maximize its therapeutic potential.
Target Audience
Enoda's primary audience includes researchers and pharmaceutical companies involved in cell therapy development, seeking to enhance the therapeutic potential of cells for various diseases.
Features
- Molecular tooling platform for mapping underexplored pathways
- High-throughput screening to identify optimal cell phenotypes
- Systems immunology to engineer the right cell type